Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study
Authors' conclusion
Combining SGLT2i and pioglitazone is a potentially useful strategy to ameliorate 'at-risk' MASH in patients with type 2 diabetes.
Study context
- Population
- Patients with T2D with longitudinal FibroScan-aspartate aminotransferase (FAST) score measurements
- Participants
- 888 patients
- Exposure
- Combinations of pioglitazone, GLP-1 RA and/or SGLT2i vs single use or none
- Outcome
- Changes in FAST score (low FAST score at reassessment; FAST score regression)
- Follow-up
- Median 3.9 years
Methodological detailsreal-world, longitudinal, multivariable logistic regression
- Real-world
- Longitudinal
- Multivariable logistic regression
Main finding
As reported in the abstract
Odds ratio
2.84
P = 0.01
Dual combination vs Single use · low FAST score at reassessment
Odds ratio
6.51
P = 0.008
SGLT2i + pioglitazone vs None · low FAST score at reassessment; adjusted for changes in glycaemic control and body weight
Odds ratio
12.52
P = 0.009
SGLT2i + pioglitazone vs None · FAST score regression; adjusted for changes in glycaemic control and body weight
- Increasing number of agents used associated with more reductions in FAST score
- P for trend < 0.01
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →